FAQ/Help |
Calendar |
Search |
Today's Posts |
02-05-2017, 12:33 PM | #1 | |||
|
||||
Senior Member
|
Study reveals the role of Parkin and PINK1 in Parkinson's disease - CUSABIO Life science | cusabio.com
Proteasome - Wikipedia
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
02-06-2017, 06:45 PM | #2 | ||
|
|||
Member
|
The press release has some more information:
Targeting Parkinson’s-Linked Protein Could Neutralize 2 of the Disease’s Causes - 2/ 1/2 17 The research paper itself is also available: http://www.cell.com/cell-reports/abs...247(16)31812-5 (this is an "Open Access" article) |
||
Reply With Quote |
02-07-2017, 06:52 AM | #3 | ||
|
|||
Member
|
After reading this, and other, research papers, here are some thoughts. These thoughts are admittedly limited and very simplistic. Feel free to jump in and correct any mis-understandings, omissions, or any other errors.
My understanding of the "normal" relationship between the proteins PINK1, parkin, and PARIS is as follows: PINK1 proteins phosphorylate PARIS proteins, and this then enables parkin proteins to ubiquitinate PARIS proteins, and this then enables PARIS proteins to be degraded by proteasomes. This keeps the number of PARIS proteins in check, thus ensuring that dopamine neurons are not killed by excess amounts of the PARIS protein. However, in PWPs, something interferes with parkin, and this stops parkin from being able to ubiquitinate PARIS. From reference [1], there is a strong candidate for what that "something" might be, and that is the c-Abl protein. There is already at least one promising drug (nilotinib) which targets c-Abl. However, a new drug which targets PARIS directly could also be worthwhile. For example, some PWPs cannot tolerate nilotinib, even in small doses. [1] Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration, Saurav Brahmachari et al., J Clin Invest. 2016;126(8):2970–2988. doi:10.1172/JCI85456. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Apparently there are two different types of dopamine neurons | Parkinson's Disease | |||
Reversal of dopamine neurons, smilagenin. | Parkinson's Disease | |||
Dopamine neurons in parkinson | Parkinson's Disease | |||
Parkin, PINK and mt integrity: concept of mitochondrial dysfunction in PD | Parkinson's Disease | |||
Resveratol Protects Dopamine Neurons | Parkinson's Disease |